Literature DB >> 19625411

Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Behzad Etemad1, Angela Fellows, Brenda Kwambana, Anupa Kamat, Yang Feng, Sandra Lee, Manish Sagar.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein modifications over the course of infection have been associated with coreceptor switching and antibody neutralization resistance, but the effect of the changes on replication and host cell receptor usage remains unclear. To examine this question, unique early- and chronic-stage infection envelope V1-to V5 (V1-V5) segments from eight HIV-1 subtype A-infected subjects were incorporated into an isogenic background to construct replication-competent recombinant viruses. In all subjects, viruses with chronic-infection V1-V5 segments showed greater replication capacity than those with early-infection V1-V5 domains in cell lines with high levels of both the CD4 and the CCR5 receptors. Viruses with chronic-infection V1-V5s demonstrated a significantly increased ability to replicate in cells with low CCR5 receptor levels and greater resistance to CCR5 receptor and fusion inhibitors compared to those with early-infection V1-V5 segments. These properties were associated with sequence changes in the envelope V1-V3 segments. Viruses with the envelope segments from the two infection time points showed no significant difference in their ability to infect cells with low CD4 receptor densities, in their sensitivity to soluble CD4, or in their replication capacity in monocyte-derived macrophages. Our results suggest that envelope changes, primarily in the V1-V3 domains, increase both the ability to use the CCR5 receptor and fusion kinetics. Thus, envelope modifications over time within a host potentially enhance replication capacity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625411      PMCID: PMC2748008          DOI: 10.1128/JVI.00925-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  86 in total

1.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates.

Authors:  M Jansson; M Popovic; A Karlsson; F Cocchi; P Rossi; J Albert; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 3.  Coreceptors: implications for HIV pathogenesis and therapy.

Authors:  J P Moore
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

4.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

5.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

6.  HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.

Authors:  G Alkhatib; M Locati; P E Kennedy; P M Murphy; E A Berger
Journal:  Virology       Date:  1997-08-04       Impact factor: 3.616

7.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

8.  Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages.

Authors:  S R Lewin; S Sonza; L B Irving; C F McDonald; J Mills; S M Crowe
Journal:  AIDS Res Hum Retroviruses       Date:  1996-07-01       Impact factor: 2.205

9.  Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR.

Authors:  R A Fouchier; M Brouwer; S M Broersen; H Schuitemaker
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  31 in total

1.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

2.  Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors:  Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.

Authors:  Nicole Espy; Beatriz Pacheco; Joseph Sodroski
Journal:  Virology       Date:  2017-05-15       Impact factor: 3.616

Review 4.  Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.

Authors:  Mario V Beccari; Bryan T Mogle; Eric F Sidman; Keri A Mastro; Elizabeth Asiago-Reddy; Wesley D Kufel
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

5.  Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains.

Authors:  Marielle Cavrois; Jason Neidleman; Mario L Santiago; Cynthia A Derdeyn; Eric Hunter; Warner C Greene
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

6.  Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.

Authors:  Behzad Etemad; Melissa Ghulam-Smith; Oscar Gonzalez; Laura F White; Manish Sagar
Journal:  J Virol Methods       Date:  2015-02-11       Impact factor: 2.014

7.  Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.

Authors:  Manish Sagar; Hisashi Akiyama; Behzad Etemad; Nora Ramirez; Ines Freitas; Suryaram Gummuluru
Journal:  J Infect Dis       Date:  2012-03-06       Impact factor: 5.226

8.  Efficiency of CCR5 coreceptor utilization by the HIV quasispecies increases over time, but is not associated with disease progression.

Authors:  Andrew D Redd; Oliver Laeyendecker; Xiangrong Kong; Noah Kiwanuka; Tom Lutalo; Wei Huang; Ronald H Gray; Maria J Wawer; David Serwadda; Susan H Eshleman; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

9.  Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.

Authors:  Melissa Alexander; Rebecca Lynch; Joseph Mulenga; Susan Allen; Cynthia A Derdeyn; Eric Hunter
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

10.  Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions.

Authors:  Andrew D Redd; Aleisha N Collinson-Streng; Nikolaos Chatziandreou; Caroline E Mullis; Oliver Laeyendecker; Craig Martens; Stacy Ricklefs; Noah Kiwanuka; Phyu Hninn Nyein; Tom Lutalo; Mary K Grabowski; Xiangrong Kong; Jordyn Manucci; Nelson Sewankambo; Maria J Wawer; Ronald H Gray; Stephen F Porcella; Anthony S Fauci; Manish Sagar; David Serwadda; Thomas C Quinn
Journal:  J Infect Dis       Date:  2012-09-19       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.